JPWO2023059795A5 - - Google Patents
Info
- Publication number
- JPWO2023059795A5 JPWO2023059795A5 JP2024521023A JP2024521023A JPWO2023059795A5 JP WO2023059795 A5 JPWO2023059795 A5 JP WO2023059795A5 JP 2024521023 A JP2024521023 A JP 2024521023A JP 2024521023 A JP2024521023 A JP 2024521023A JP WO2023059795 A5 JPWO2023059795 A5 JP WO2023059795A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- taxane
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252995P | 2021-10-06 | 2021-10-06 | |
| US63/252,995 | 2021-10-06 | ||
| PCT/US2022/045895 WO2023059795A1 (en) | 2021-10-06 | 2022-10-06 | Combination therapies using prmt5 inhibitors for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024538719A JP2024538719A (ja) | 2024-10-23 |
| JPWO2023059795A5 true JPWO2023059795A5 (https=) | 2025-10-20 |
| JP2024538719A5 JP2024538719A5 (https=) | 2025-10-20 |
Family
ID=84053165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521023A Pending JP2024538719A (ja) | 2021-10-06 | 2022-10-06 | がんの治療のためのｐｒｍｔ５阻害剤を使用する併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240398795A1 (https=) |
| EP (1) | EP4412607A1 (https=) |
| JP (1) | JP2024538719A (https=) |
| KR (1) | KR20240095421A (https=) |
| CN (1) | CN118251218A (https=) |
| AU (1) | AU2022360837A1 (https=) |
| CA (1) | CA3233157A1 (https=) |
| IL (1) | IL311663A (https=) |
| MX (1) | MX2024004171A (https=) |
| WO (1) | WO2023059795A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023202626A1 (zh) * | 2022-04-22 | 2023-10-26 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| CN119301101A (zh) * | 2022-07-29 | 2025-01-10 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0922332D0 (en) * | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| EP3177288A4 (en) * | 2014-08-04 | 2018-04-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3191592A1 (en) * | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| TW202122387A (zh) | 2019-09-12 | 2021-06-16 | 美商米瑞替療法公司 | Mta協同性之prmt5抑制劑 |
| AU2020410418A1 (en) * | 2019-12-18 | 2022-06-09 | Pfizer Inc. | Once daily cancer treatment regimen with a PRMT5 inhibitor |
| WO2021138578A1 (en) * | 2019-12-31 | 2021-07-08 | The Trustees Of Indiana University | Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5 |
-
2022
- 2022-10-06 EP EP22800027.9A patent/EP4412607A1/en active Pending
- 2022-10-06 AU AU2022360837A patent/AU2022360837A1/en active Pending
- 2022-10-06 CA CA3233157A patent/CA3233157A1/en active Pending
- 2022-10-06 MX MX2024004171A patent/MX2024004171A/es unknown
- 2022-10-06 US US18/697,932 patent/US20240398795A1/en active Pending
- 2022-10-06 JP JP2024521023A patent/JP2024538719A/ja active Pending
- 2022-10-06 WO PCT/US2022/045895 patent/WO2023059795A1/en not_active Ceased
- 2022-10-06 KR KR1020247014554A patent/KR20240095421A/ko active Pending
- 2022-10-06 IL IL311663A patent/IL311663A/en unknown
- 2022-10-06 CN CN202280067397.9A patent/CN118251218A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12453712B2 (en) | Antitumoral use of cabazitaxel | |
| JP2025020147A5 (https=) | ||
| JP2023501627A (ja) | Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| CN113573736B (zh) | 经修饰的微rna和它们在治疗癌症中的用途 | |
| JP2015514109A5 (https=) | ||
| JPWO2006080327A1 (ja) | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 | |
| EP3600341A1 (en) | Gemcitabine derivatives for cancer therapy | |
| JPWO2023196545A5 (https=) | ||
| JPWO2021030706A5 (https=) | ||
| CN101687104A (zh) | 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 | |
| Lagunes et al. | A narrative review of chemotherapy in advanced triple negative breast cancer | |
| US10080807B2 (en) | Combination chemotherapy comprising a liposomal prodrug of mitomycin C | |
| Parizadeh et al. | Epigenetic drug therapy in the treatment of colorectal cancer | |
| JPWO2023059795A5 (https=) | ||
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| CN1917885A (zh) | 抗癌疗法 | |
| JPWO2022076859A5 (https=) | ||
| CN101355969B (zh) | 包含cyc-682和细胞毒性药物的抗增殖性组合 | |
| Ozdemir et al. | Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients | |
| EP3349799A1 (en) | Combinations of a mithramycin analogue and another chemotherapeutic agent for the treatment of triple negative breast cancer | |
| JP6488280B2 (ja) | タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| CN106176757B (zh) | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 | |
| JP2015199678A (ja) | ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2023040314A (ja) | ウラシル誘導体化合物を含有する抗腫瘍効果増強剤 |